Analysis shows elevated risk of obstetric complications in women with obesity and specific gene polymorphisms, suggesting personalized care strategies.
The combination of maternal obesity and thrombophilic gene polymorphisms (PAI-1, F5, F2, FGB) significantly increases the risk of obstetric complications. Obesity-related metabolic disturbances – hyperinsulinemia and elevated proinflammatory cytokines – enhance the expression of these genes, leading to pronounced hemostatic disorders: hypercoagulability, hypofibrinolysis, and impaired placentation. Clinically, this manifests as increased incidence of preeclampsia, fetal growth restriction, gestational diabetes mellitus, and venous thromboembolism. The impact of specific polymorphisms (particularly F2 and FGB) shows significant heterogeneity, strongly dependent on patients' ethnic background and combinatorial genetic interactions. For instance, while PAI-1 4G/5G demonstrates consistent risk associations in certain populations, isolated F5 Leiden rarely correlates with placental complications without synergistic interaction with PAI-1 or obesity. Addressing these challenges requires personalized strategies. Anticoagulant therapy (low molecular weight heparins) proves effective primarily in high thrombotic risk cases, but managing placental insufficiency necessitates additional metabolic control through weight reduction and insulin resistance correction. Future research priorities include developing ethnically adapted algorithms incorporating combinatorial genetic profiling and dynamic biomarker monitoring.
No takes yet. Share an insight, caveat, or question.
Mukhtarova et al. (2025) studied this question.